Production of Neutralizing Antibody

Area of Science:

• Biotechnology
• Immunology
• Biopharmaceutical Development

Background:

• Monoclonal antibodies (mAbs) are crucial in early-stage biologic development due to their specificity, homogeneity, and scalability.
• mAbs serve as foundational materials for antibody fragments and engineered immunomodulatory antibodies.
• Their utility in basic rheumatoid arthritis (RA) research is well-documented.

Purpose of the Study:

• To introduce the fundamental hybridoma technique for monoclonal antibody (mAb) production.
• To outline the key steps involved in the hybridoma technique, from immunization to purification.
• To highlight the application of synthetic proteoliposomes for targeting membrane proteins.

Main Methods:

• The hybridoma technique involves animal immunization, cell fusion, hybridoma screening, expansion of positive hybridomas, and antibody purification.
• Synthetic proteoliposomes are employed during immunization and screening phases.
• These methods facilitate the generation of mAbs with specific affinity, particularly for membrane proteins.

Main Results:

• The hybridoma technique provides a feasible and established method for producing high-quality monoclonal antibodies.
• Successful application of synthetic proteoliposomes enables targeted antibody generation against specific membrane proteins.
• The described process yields homogeneous and specific mAbs suitable for large-scale production.

Conclusions:

• The hybridoma technique remains a cornerstone for producing monoclonal antibodies (mAbs) for research and therapeutic development.
• The integration of synthetic proteoliposomes enhances the specificity of mAb generation, especially for challenging targets like membrane proteins.
• This chapter provides a comprehensive overview of a critical method in antibody engineering and biopharmaceutical innovation.